Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 592

Similar articles for PubMed (Select 18355421)

1.

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J.

Curr Med Res Opin. 2008 May;24(5):1237-54. doi: 10.1185/030079908X291985 . Epub 2008 Mar 19. Review.

PMID:
18355421
2.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

3.
4.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

5.

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.

Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.

Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Review.

PMID:
18547300
6.

Cost effectiveness of biologic therapies for plaque psoriasis.

Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.

Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Review.

PMID:
23696234
7.

[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].

Zhang Z, Schmitt J, Wozel G, Kirch W.

Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. Epub 2009 Feb 26. German.

PMID:
19242664
8.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
9.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Review.

PMID:
21910698
10.

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.

Katugampola RP, Lewis VJ, Finlay AY.

Br J Dermatol. 2007 May;156(5):945-50. Epub 2007 Mar 28. Review.

PMID:
17388922
11.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
12.

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.

J Am Acad Dermatol. 2013 Sep;69(3):385-92. doi: 10.1016/j.jaad.2013.03.031. Epub 2013 May 1.

PMID:
23643256
13.

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

Arch Dermatol. 2005 Jan;141(1):31-8.

PMID:
15655139
14.

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W.

Br J Dermatol. 2008 Sep;159(3):513-26. doi: 10.1111/j.1365-2133.2008.08732.x. Epub 2008 Jul 9. Review.

PMID:
18627372
15.
16.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
17.

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.

Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR.

J Am Acad Dermatol. 2008 Jan;58(1):125-35. Epub 2007 Nov 8. Review.

PMID:
17996329
18.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
19.

Infliximab for the treatment of adults with psoriasis.

Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.

Health Technol Assess. 2009 Jun;13 Suppl 1:55-60. doi: 10.3310/hta13suppl1/09.

20.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk